Skip to main content
. 2020 May 15;67(3):323–331. doi: 10.3164/jcbn.20-27

Table 2.

Clinicopathologic features of patients with Intrahepatic cholangiocarcinoma

Item CONUT <3 (n = 112) CONUT ≥3 (n = 57) p
Age 57.19 ± 9.36 59.47 ± 8.12 0.103
Gender (male:female) 67:44 28:28 0.251
History of long-term alcohol consumption 28 (25.0) 11 (19.3) 0.406
History of biliary stones 16 (14.3) 12 (21.1) 0.263
HBsAg (+) 28 (25.0) 7 (12.3) 0.069
Liver cirrhosis 49 (43.8) 13 (23.2) 0.009*
Preoperative therapy 7 (6.3) 4 (7.0) 0.848
Tumor margin (<1 mm) 42 (37.5) 30 (52.6) 0.094
Mass-forming tumor 111 (99.1) 54 (94.7) 0.258
Centre-located tumor 60 (53.6) 25 (43.9) 0.233
Poorly differentiated 62 (55.4) 33 (57.9) 0.867
Multiple tumors 19 (17.0) 14 (24.6) 0.303
Tumor size (cm) 4.860 ± 2.1814 6.779 ± 2.6321 0.000*
TNM stage: T1 58 (51.8) 21 (36.8) 0.066
TNM stage: T2 31 (27.7) 16 (28.1) 0.957
Positive lymph node metastasis (TNM stage: N1) 18 (16.1) 26 (45.6) 0.000*
Microvascular invasion 39 (34.8) 22 (38.6) 0.734
Capsular invasion 80 (71.4) 45 (78.9) 0.244
Perineural invasion 29 (25.8) 27 (47.3) 0.006*
Postoperative therapy before recurrence 41 (36.7) 23 (40.4) 0.489
Preoperative CEA (ng/ml) 6.60 ± 35.28 18.69 ± 50.15 0.109
Preoperative CA199 (U/ml) 501.79 ± 3,183.57 1,792.14 ± 2,874.04 0.015*
Preoperative GGT (U/L) 101.17 ± 191.25 118.18 ± 173.92 0.574
Preoperative ALP (U/L) 98.13 ± 101.70 123.56 ± 80.12 0.102
Preoperative TBIL (µmol/L) 16.16 ± 20.61 19.06 ± 52.88 0.611
Preoperative ALT (U/L) 34.45 ± 52.44 34.53 ± 68.21 0.993
Preoperative AST (U/L) 29.07 ± 29.02 29.46 ± 30.91 0.938

Data are the mean with SD in parentheses for continuous variables, with p values from t tests; data are numbers with percentages in parentheses for categorical variables, with p values from chi-square test, *significant at p<0.05.